Literature DB >> 7285483

Cigarette smoking and theophylline clearance and metabolism.

J J Grygiel, D J Birkett.   

Abstract

Differences in plasma theophylline clearance (ClT) and metabolism between smoking and nonsmoking normal subjects were examined by analysis of plasma and urinary theophylline concentrations and of urinary metabolite concentrations under steady-state oral dosing conditions. ClT in smokers (0.053 +/- 0.006 1 . hr-1 . kg-1) was greater than in nonsmokers (0.032 +/- 0.002 l . hr-1 . kg-1, p less than 0.005). Analyses of urinary metabolites revealed that clearance to l-methyluric acid (Cl1MU) and clearance to 3-methylxanthine (Cl3MX) were increased in smokers 1.99-fold and 2.10-fold over nonsmoking controls (P less than 0.005). Clearance to 1.3-dimethyluric acid (ClDMU) was also enhanced in smokers 1.68-fold compared to controls (P less than 0.01). The positive relationship between Cl1MU and Cl3MX in both smokers and nonsmokers (r = 0.98, P less than 0.001) supports the concept that two N-demethylation pathways for theophylline metabolism are under common regulatory control and involve a form of cytochrome P450 distinct from that mediating 8-hydroxylation of theophylline to DMU. These results suggest that cigarette smoking induces both of the cytochrome P450-mediated pathways of theophylline metabolism but that N-demethylation may be increased to a greater extent than 8-hydroxylation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7285483     DOI: 10.1038/clpt.1981.193

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  35 in total

1.  Lack of effect of terfenadine on theophylline pharmacokinetics and metabolism in normal subjects.

Authors:  N Brion; E Naline; D Beaumont; M Pays; C Advenier
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

2.  Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.

Authors:  K Kobayashi; M Nakajima; K Chiba; T Yamamoto; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

3.  Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man.

Authors:  J O Miners; L M Wing; K J Lillywhite; R A Robson
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

Review 4.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

5.  Metabolism of theophylline by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; A U Freiburghaus; F Follath
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

Review 6.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2.

Authors:  K Brøsen
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

7.  The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women.

Authors:  K Groen; M A Horan; N A Roberts; R S Gulati; B Miljkovic; E J Jansen; V Paramsothy; D D Breimer; C F van Bezooijen
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

8.  Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.

Authors:  Janne T Backman; Marika T Schröder; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2007-10-23       Impact factor: 2.953

9.  Specificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition.

Authors:  R A Robson; J O Miners; A G Whitehead; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

10.  Induction of cytochrome P-448 iso-enzymes and related glucuronyltransferases in the human liver by cigarette smoking.

Authors:  R Fleischmann; H Remmer; U Stärz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.